A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis

Trial Profile

A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Spondylarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms COAST-X
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Aug 2017 Planned number of patients changed from 300 to 305.
    • 01 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
    • 27 Jul 2017 Planned End Date changed from 1 Jul 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top